AndzonBio2 Partners with Cambridge to Innovate Neuroinflammation Therapies

AndzonBio2 and Cambridge Collaboration on Neuroinflammation Therapies

AndzonBio2, renowned for its innovative approach in neuroscience, has proclaimed an exciting collaboration with the ALBORADA Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise. The aim of this partnership is to explore new therapeutic avenues for neuroinflammation, a critical factor in numerous neurodegenerative and neurological disorders such as Parkinson's, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).

Neurodegenerative diseases impact over 3 billion individuals globally, yet effective treatments to halt or modify the progression of these diseases remain elusive. Recent scientific studies increasingly showcase neuroinflammation as a key biological mechanism in disease progression, identifying it as a significant target for therapeutic innovation.

Under the formal agreements, AndzonBio2 will leverage its early drug development expertise alongside the exceptional neuroscience capabilities from both Cambridge and ADDI. This synergistic effort aims to advance a pioneering therapeutic program designed to modulate essential pathways involved in neuroinflammatory processes. The program builds upon cutting-edge biology and represents a rapidly evolving area of scientific and commercial interest.

Loic Lhuillier, CEO of AndzonBio2, expressed enthusiasm about the partnership: "We are thrilled to initiate this collaboration with ADDI from Cambridge. Neuroinflammation underpins many severe brain disorders, creating an urgent need for new therapeutic solutions. By combining our complementary strengths, we have a unique opportunity to accelerate the development of a revolutionary therapeutic approach, potentially transforming treatment landscapes for patients."

Cambridge Enterprise will provide AndzonBio2 with exclusive licensing options for the intellectual property arising from this collaboration, facilitating the program through preclinical and clinical development phases. The partnership is meticulously structured to efficiently merge academic discovery with industrial-level drug development, enabling expedited progress towards candidate selection and subsequent clinical trials.

Professor John Skidmore, scientific director of the ALBORADA Drug Discovery Institute at the University of Cambridge, remarked on the collaboration's significance: "We are delighted to work with AndzonBio2 on this promising initiative. This partnership exemplifies our commitment to transforming cutting-edge neuroscience into effective therapies. AndzonBio2 brings specialized knowledge in neuroinflammation and drug development that will be instrumental in advancing this exciting program."

This collaborative agreement reinforces the missions of Cambridge and ADDI in driving neuroscience innovation through partnerships with organizations capable of translating scientific discoveries into tangible therapeutic opportunities.

About AndzonBio2

AndzonBio2 is a pioneering neuroscience company with an innovative model that efficiently transforms scientific advancements into therapeutic solutions aimed at addressing the underlying causes of neurological diseases. The company strategically focuses on neuroinflammation, increasingly recognized for its fundamental role in various brain disorders. AndzonBio2 seeks to identify, evaluate, and integrate the most promising European projects to cultivate and establish a leading asset portfolio with a balanced risk-benefit ratio in neurology.

For more information, visit AndzonBio2.

About Cambridge Enterprise

Cambridge Enterprise connects and facilitates the transformation of Cambridge research into global impact. As the innovative arm of the University of Cambridge, we support the application of Cambridge research to create world-leading economic and social impact. From idea development to investment, we provide comprehensive support for researchers, innovators, and talented teams tackling the challenges of today's world.

For further details, visit Cambridge Enterprise.

About ALBORADA Drug Discovery Institute

Funded by Alzheimer's Research UK and the ALBORADA Trust, the ALBORADA Drug Discovery Institute is developing the next generation of treatments for diseases causing dementia. ADDI bridges deep academic knowledge of diseases with the drug development capabilities of the pharmaceutical and biotechnology industries, as well as centres of clinical excellence. Established in 2014 with funding from Alzheimer's Research UK, ADDI forms part of a broader alliance for drug discovery.

For more information, contact:
Loic Lhuillier, PhD
Co-founder & CEO
Email: [email protected]